CB2 definition

CB2 means the convertible bonds in the aggregate principal amount of US$7,000,000 due in 2021 of which the Company denies its validity. Please refer to the Company's announcement dated 12 April 2019 for details;
View Source
CB2. The term “CB2” shall apply to a full-scholarship work study dancer who is cast in corps roles only. (1) For NUTCRACKER and one other full length ballet, Company may utilize up to twelve (12) CB2s. Otherwise, the ratio of CB2s will be as described in #2 below. (a) EMPLOYER may utilize additional students only after engaging the number of Guaranteed Employment Dancers specified above and CB2s. (b) CB2s shall not be cast over Company Dancers. (c) CB2s shall rehearse and perform with other ARTISTS in accordance with company schedule, and may also take classes, do outside engagements or any other activities that the EMPLOYER may require them to do. (2) No CB2 shall be allowed to fill in for a Company Dancer during a rehearsal except as follows. (a) No CB2 may stand in for a Principal or Soloist role. (b) For New Works only, where no other cast member is available, a CB2 can stand in for a work through rehearsal when working on the choreographic process. At the end of that rehearsal, the CB2 can participate in a run through of that section only. (3) Employer shall pay CB2s an education stipend of a minimum $150.00 per week. This rate applies during all company guaranteed work weeks in a season and EMPLOYER shall provide shoes. CB2s do not pay AGMA dues or any other related AGMA fees. The EMPLOYER’s Artistic Staff will make best efforts to have a balanced CB2 company consisting of equal male-presenting and female-presenting ARTISTS, keeping the repertoire requirements in mind. (4) CB2s shall be engaged during a period not to exceed two full seasons. (5) EMPLOYER is granted an exception to the rules in this section to allow a CB2 to be cast in an Apprentice role (see rules for casting Apprentices in 38 (a)(4)) in any Production including New Works with no additional compensation due. This shall be referred to as a “bump-up” and each CB2 is allowed this bump-up one time per season. Should the said CB2 receive a bump-up a 2nd time within their season, EMPLOYER must raise said CB2 to the Apprentice rank (following all casting rules for that rank) from that point to the end of the season. Compensation will be due from the first day of rehearsal (as long as said CB2 was cast in that role), unless bump up is due to emergency or illness, in which case compensation will be due from the moment the CB2 takes over the role. Furthermore, should the CB2 be promoted to Apprentice and work 20 weeks or more at the new rank, the Apprentice shall be considered to have completed an ...
View Source

Examples of CB2 in a sentence

  • Group C-B Certificates The Class C-B-1, Class C-B-2, Class C-B-3, Class C-B-4, Class C-B-5 and Class C-B-6 Certificates.

  • The endocannabinoid system (ECS) is a widely distributed signaling system in the brain, involving cannabinoid receptors 1 and 2 (CB1 and CB2) and their best known endogenous agonists N-arachidonoyl ethanolamine (anandamide, AEA) and 2-arachidonoyl glycerol (2- AG), which are defined as endocannabinoids (eCBs)1.

  • Group C-B Certificates: The Class C-B-1, Class C-B-2, Class C-B-3, Class C-B-4, Class C-B-5 and Class C-B-6 Certificates.

  • You will be based at the CUSU offices in Cambridge (Old Examination Hall, Free School Lane, Cambridge CB2 3RF) [or alternative offices as would be identified as the offices of the CUSU], although frequently you will be required to work elsewhere in the University of Cambridge and its constituent Colleges.

  • Subordinate Certificate: Any of the Class C-B-1, Class C-B-2, Class C-B-3, Class C-B-4, Class C-B-5, Class C-B-6, Class 1-B-1 or Class 1-B-2 Certificates.

  • The Class C-B-1, Class C-B-2, Class C-B-3, Class C-B-4, Class C-B-5 and Class C-B-6 Certificates.

  • CB2 plays a central role in modulating and resolving inflammation by, in effect, turning heightened inflammation “off” and restoring homeostasis.

  • Our lead investigational drug candidate, lenabasum, is a novel, synthetic, oral, cannabinoid type 2, or CB2, agonist designed to resolve chronic inflammation, limit fibrosis and support tissue repair.

  • Lenabasum selectively binds to CB2 in the periphery, which is preferentially expressed on activated immune cells, fibroblasts and other cell types, including muscle and bone cells.

  • This has been demonstrated in animal models lacking CB2 as well as humans with genetic polymorphism in the CB2 gene, as these exhibit excessive inflammation and fibrosis in response to activators of the innate immune system.